Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGLIO: L19TNF +/- Chemo in Recurrent IDH-mutant Glioma
NCT07120984Phase 2Not yet recruiting
- Sponsor
- Philogen
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 2, open-label trial of onfekafusp alfa in astrocytoma and Oligodendroglioma (OG) (7 cohorts), sponsored by Philogen. Primary endpoint: Progression Free Survival Rate at 12 months (PFS-12). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT07120984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120984.